GlassScriptPhysician profile
Jose Acosta
NPI 1720085434
$4,424.42
in general payments reported to CMS, 2019-2025
28 companies · $960 in 2025
The $960 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $994 · 2022: $754 · 2023: $720 · 2024: $996 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $917.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.98 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $604.61 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $282.04 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $245.99 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $241.54 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $234.02 | 2021 | |
| Axsome Therapeutics, INC. | $213.71 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $143.82 | 2021-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Sumitomo Pharma America, INC. | $94.50 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $93.15 | 2023-2025 | Shingrix, Arexvy |
| Madrigal Pharmaceuticals | $92.56 | 2024-2025 | Resmetirom, Rezdiffra |
| Dynavax Technologies Corporation | $91.91 | 2024-2025 | Heplisav-B |
| Abbvie INC. | $74.07 | 2022-2024 | Vraylar |
| Abbott Laboratories | $70.67 | 2021-2025 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $55.25 | 2021-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.06 | 2024-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $34.89 | 2022 | |
| Amgen INC. | $24.39 | 2021 | |
| Lundbeck LLC | $22.11 | 2025 | Rexulti |
| Mylan Specialty L.P. | $20.92 | 2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $20.45 | 2024 | Camzyos |
| Esperion Therapeutics, INC. | $18.52 | 2021 | |
| Corcept Therapeutics | $18.41 | 2025 | Korlym |
| Astellas Pharma US INC | $17.63 | 2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $16.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.11 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.